Skip to main content
. Author manuscript; available in PMC: 2015 Nov 3.
Published in final edited form as: Inhal Toxicol. 2014 Feb 6;26(4):240–249. doi: 10.3109/08958378.2014.880202

Figure 1.

Figure 1

Outline of experimental animal groups used to assess MWCNT-induced changes in pulmonary resistance. C57BL/6 and IL-33−/− mice were instilled with MWCNTs and baseline pulmonary function was assessed 30 days post exposure (C57BL/6 n=18/group; IL-33−/− n=8/group) (A). Changes in airway hyperresponsiveness (AHR) were evaluated in a separate cohort of C57BL/6 and IL-33−/− mice via methacholine challenges 30 days following MWCNT instillation (n=6/group) (B). C57BL/6 mice underwent albuterol treatment 30 days after MWCNT instillation to determine the contribution of airway smooth muscle contraction to MWCNT-induced pulmonary resistance changes (vehicle n=4/group; MWCNT n=8/group) (C). Lastly, a separate group of C57BL/6 mice were treated with methylprednisolone, 30 min prior to and every 7 days following instillation of MWCNTs, and changes in baseline pulmonary function were determined (n=6/group) (D).